25 North 38th Street
11th Floor
Philadelphia, PA 19104
United States
267 817 5790
https://www.centurytx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 152
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Brent Pfeiffenberger M.B.A., Pharm.D. | CEO & Director | 274.06k | N/D | N/D |
Dr. Adrienne Farid Ph.D. | COO & Head of Early Development | 670.29k | N/D | 1962 |
Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer | 852.56k | N/D | 1967 |
Mr. Douglas Carr CPA | Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary | N/D | N/D | N/D |
Mr. Kenneth J. Dow J.D. | Senior VP of General Counsel | N/D | N/D | N/D |
Dr. Shane Williams Ph.D. | Chief People Officer | N/D | N/D | N/D |
Dr. Hyam I. Levitsky M.D. | President of Research & Development | 502.12k | N/D | 1958 |
Michael Naso Ph.D. | Senior VP of Cell Engineering | N/D | N/D | N/D |
Dr. Nick Trede M.D., Ph.D. | Senior VP & Head of Clinical Development | N/D | N/D | N/D |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
La calificación ISS Governance QuickScore de Century Therapeutics, Inc. a partir del 1 de junio de 2024 es 7. Las puntuaciones principales son Auditoría: 8; Junta: 5; Derechos del accionista: 8; Compensación: 8.